A U.S. government scientist who oversees the team responsible for collecting data on COVID-19 and RSV hospitalizations used ...

For the 2025-2026 respiratory viral season, Moderna intends to have mResvia available for both FDA-approved patient populations.

The FDA expanded its approval of Moderna's RSV vaccine on Thursday to include adults under age 60 at increased risk of the ...

A Centers for Disease Control and Prevention official who led the agency's network to study hospitalization trends from infectious diseases like COVID-19 has resigned in protest following Health and ...

Expanded indication builds on existing U.S. FDA approval of mRESVIA for adults aged 60 and older CAMBRIDGE, MA / ACCESS ...

The U.S. Food and Drug Administration on Thursday expanded the use of Moderna's respiratory syncytial virus vaccine to a ...

The 17 members of the CDC's vaccine advisory committee, who were ousted last week, argued their abrupt dismissal has "left ...

Moderna's shares fell 2.3% on Friday on concerns about whether a new CDC advisory panel would back the use of the company's ...

Fiona Havers, who oversaw CDC respiratory virus data, told colleagues she no longer had confidence the data would be used ...

The Food and Drug Administration expanded the approval of Moderna’s RSV vaccine on Thursday, extending the license to include ...

The Food and Drug Administration (FDA) expanded the approval of Moderna’s RSV vaccine late Thursday to include people 18 to ...

The FDA expanded the approval of Moderna’s RSV vaccine, extending the license to include more adults and giving the company a ...